Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.

Journal of hepatology - 1 Nov 1996

Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O

Abstract excerpt

BACKGROUND/AIMS: Small, uncontrolled studies of ribavirin for patients with chronic hepatitis C have reported efficacy in chronic hepatitis C. We have evaluated the efficacy and safety of a 24-week course of oral ribavirin in patients with chronic hepatitis C, compared to placebo. METHODS: A total of 114 patients were randomised to ribavirin or placebo. Ribavirin was administered in doses of 1000 or 1200 mg/day...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Biopsy

Share to Chronic Disease

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Source

Identifiers

PMID: 8938532
DOI: 10.1016/s0168-8278(96)80225-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.PMID 8938532Read ↗

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.Semantic proximity Read ↗

Ribavirin in the treatment of chronic hepatitis C.Semantic proximity Read ↗

Ribavirin in the treatment of hepatitis C.Semantic proximity Read ↗

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.Semantic proximity Read ↗

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Semantic proximity Read ↗

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial.Semantic proximity Read ↗

Ribavirin: current role in the optimal clinical management of chronic hepatitis C.Semantic proximity Read ↗

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.Semantic proximity Read ↗

Treatment of naive patients with chronic hepatitis C.Semantic proximity Read ↗

Long-term administration of natural interferon-alpha in patients with chronic hepatitis C: relationship to serum RNA concentration, HCV-RNA genotypes, histological changes and hepatitis C virus.Semantic proximity Read ↗

Pilot study of interferon gamma for chronic hepatitis C.Semantic proximity Read ↗

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.